Orexin-B

What it is

Orexin-B (also known as Hypocretin-2) is a 28-amino-acid neuropeptide produced by a small population (~10,000–20,000) of neurons in the lateral hypothalamic area (LHA) and perifornical area. It is cleaved from the prepro-orexin precursor protein, which also yields Orexin-A (Hypocretin-1, 33 amino acids). Orexin-B is considered the phylogenetically ancestral form of the two orexin peptides, and OX2R (the orexin-2 receptor) is the prototype receptor conserved across all vertebrates. See also our page on Orexin A for the companion neuropeptide with distinct receptor selectivity. Orexin-B activates two G-protein-coupled receptors: OX1R (orexin-1 receptor) and OX2R (orexin-2 receptor). Orexin-B has approximately equal affinity for both receptors in most species, though OX2R is the primary receptor mediating its wakefulness-promoting effects. In contrast, Orexin-A has 10-fold higher affinity for OX1R vs. OX2R. Both receptors are Gq/11-coupled (and to a lesser extent Gs-coupled), with activation triggering PKC, ERK1/2, intracellular calcium release, and cAMP-dependent pathways depending on cell type. Orexinergic neurons project widely throughout the brain to monoaminergic nuclei (locus coeruleus/norepinephrine, dorsal raphe/serotonin, tuberomammillary nucleus/histamine), cholinergic basal forebrain, and brainstem reticular formation (PMID 28012091, PMID 39706239). These projections excite arousal-promoting neurons, stabilizing the wake state and preventing inappropriate state transitions. Selective loss of orexin neurons causes narcolepsy type 1 — characterized by excessive daytime sleepiness and cataplexy — demonstrating that the orexin system is non-redundant for normal wakefulness maintenance. Beyond wakefulness, Orexin-B and OX2R are expressed in reproductive tissues including epididymal epithelium, suggesting local paracrine roles in reproductive function. In the retina, Orexin-B suppresses GABAC-mediated inhibitory currents in rod bipolar cells via OX1R and OX2R, potentially enhancing visual signal-to-noise during the active (wake) phase. Orexin-B projections also innervate the superior salivatory nucleus, implicating the system in autonomic control of salivary secretion. Regarding addiction, orexin neurons become activated by drug-associated cues and drive goal-directed drug-seeking behavior through OX1R and OX2R in cortical and subcortical circuits.

Class: Endogenous hypothalamic neuropeptide / dual orexin receptor agonist / wakefulness and arousal promoter

What it's studied for

• Narcolepsy and sleep-wake disorder — mechanistic role of orexin deficiency Mixed
  • Narrative review: >90% of narcolepsy type 1 (NT1) patients have CSF orexin-A below 110 pg/mL; postmortem shows ~95% loss of lateral hypothalamic orexin neurons. 2024 multicenter trial of danavorexton (selective OX2R agonist) showed 11.1-point improvement on Maintenance of Wakefulness Test, surpassing modafinil. Review PMID 41076550 Rauf R et al. Brain Behav. 2025.
  • Review: orexin receptor antagonists (suvorexant, daridorexant) approved for insomnia; OX2R agonists in Phase II/III for narcolepsy. Documents dual therapeutic utility of targeting the same system (agonism for narcolepsy, antagonism for insomnia). OX2R-selective agonist approach mirrors orexin-B's natural preference. PMID 42533134 Kornum BR et al. Nat Rev Endocrinol. 2026.
  • Review: orexin-B's mechanism via HCRT-1R and HCRT-2R regulates arousal, metabolism, feeding, and emotional states. NT1 patients paradoxically gain weight despite reduced caloric intake, indicating metabolic dysfunction beyond sleep. Therapeutically: TAK-861 and ALKS-2680 (OX2R agonists) in active clinical trials. OX2R PMID 40927422 Wang Y et al. Front Neurosci. 2025.
• Arousal and wakefulness regulation — neurochemical mechanisms Animal studies only
  • Review: orexinergic neurons project to locus coeruleus, dorsal raphe, tuberomammillary nucleus, and cholinergic basal forebrain to promote arousal. Selective orexin neuron loss (rather than widespread hypothalamic damage) causes narcolepsy, establishing non-redundancy of the orexin circuit. Orexin-B/Hypocretin-2 system PMID 28012091 Li SB et al. Curr Top Behav Neurosci. 2017.
  • Review: orexin neuronal projections to monoaminergic and cholinergic nuclei activate arousal. Distinct neural pathways mediate wakefulness versus sleep. Immunological factors link to orexin neuron loss in NT1. Specific projection mapping identifies anatomical basis for orexin-B's arousal effects. PMID 39706239 Li N et al. Brain Res. 2025.
  • Review: orexinergic neurons in lateral hypothalamus and perifornical area fire spontaneously correlated with arousal states. Orexin peptides exert postsynaptic excitatory effects on hypothalamic and brainstem nuclei through OX1R and OX2R activation. Loss of these neurons causes narcolepsy. PMID 39092633 Chen XY et al. J Neurochem. 2024.
• Retinal function — visual signal modulation during wake phase Animal studies only
  • Rat retina study: intravitreal orexin-B injection increased scotopic electroretinographic responses (enhanced rod bipolar cell activity). Patch-clamp: orexin-B suppressed GABAC receptor-mediated (not GABAA) inhibitory currents through OX1R and OX2R via Gi/o and PKC signaling independent of calcium or PLC. Authors propo PMID 29325900 Zhang G et al. Neuropharmacol. 2018.
• Reproductive function — epididymal biology Animal studies only
  • Immunohistochemistry in rat epididymis: intense staining for orexin-B and OX2R in principal cells of epididymal epithelium across caput, corpus, and cauda. Absent in OX receptor knockout mice (specificity confirmed). First definitive evidence for orexin-B/OX2R in rat epididymis, suggesting local paracrine role in repro PMID 29496265 Liguori G et al. Acta Histochem. 2018.
• Addiction and reward — orexin system involvement in drug-seeking Animal studies only
  • Review: orexin neurons activate robustly to drug-associated environmental cues, driving goal-directed drug-seeking via OX1R and OX2R in cortical and subcortical circuits. Both receptor subtypes are involved. Orexin-B contributes to motivational salience and drug-seeking behavior, identifying OX1R and OX2R as potential PMID 35714437 Kourosh-Arami M et al. Neuropeptides. 2022.

Community-reported dosing

Tier key: Research = PMID-cited study · [C] = scraped community source · [S] = model-synthesized from aggregate community reports (softer evidence). How we source.

Safety signals

• No human safety data exists for exogenous Orexin-B administration. The peptide is not in human clinical trials as an administered compound; all safety inference is from orexin receptor agonist drug development programs. PMID 41076550
• In the retinal intravitreal study in rats, Orexin-B was well-tolerated at doses producing measurable electrophysiological effects; no adverse events described in abstract. PMID 29325900
• Native orexin peptides have poor blood-brain barrier penetration when administered peripherally, limiting both efficacy and off-target central effects from peripheral routes; direct CNS delivery carries risks inherent to intracranial administration. PMID 28012091

Contraindications

• No formal contraindications established in reviewed literature for native Orexin-B as an administered compound — it has not been evaluated in human clinical trials. Contraindications for orexin system agonists are extrapolated from drug development programs: patients with cardiovascular disease should be cautious given orexin's cardiovascular and autonomic effects. PMID 40927422
• Patients on CNS stimulants, wake-promoting agents, or other medications affecting noradrenergic, serotonergic, or histaminergic systems should be aware of potential additive arousal effects, given orexin-B's projections to these same monoaminergic nuclei. PMID 28012091